Purchase Order 75N90025P00456
Award Date
5/7/25
Potential Completion Date
6/7/25
Potential Value
$15K
Federal Agency
NIH Clinical Center
Awardee
Cerus Corporation
Ultimate Awardee
Not listed
NAICS Category
334516 - Analytical Laboratory Instrument Manufacturing
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Concord, CA 94520, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price purchase order awarded by the Defense Health Agency (DHA) to Cerus Corporation, a biomedical products company specializing in blood safety technologies. The contract is for the service and maintenance of the Cerus INTERCEPT Illuminator, which is a key component of the company's proprietary INTERCEPT Blood System. The INTERCEPT system uses riboflavin and ultraviolet light to inactivate pathogens in blood components, including platelets, plasma, and red blood cells,...
This is a firm fixed-price purchase order contract awarded by the Defense Health Agency to Cerus Corporation, a biomedical products company specializing in blood safety technologies. The contract, valued at $146,200.00, is for the procurement of INTERCEPT Blood System processing sets for dual storage. The INTERCEPT system uses riboflavin and ultraviolet light to inactivate pathogens in blood components such as platelets and plasma, enhancing blood safety. Cerus has a history of supplying its...
The National Institutes of Health (NIH) awarded a $28,924.80 firm fixed price purchase order contract to Cerus Corporation for the delivery of INTERCEPT Platelet Processing Sets with Dual Storage Containers. This sole-source contract is for the Department of Transfusion Medicine and will run from April 1, 2025 to September 30, 2025. Cerus Corporation's proprietary INTERCEPT technology is used to reduce the potential for virus replication in platelets, ensuring the safety of transfused blood...
This is a firm fixed-price purchase order contract awarded by the Defense Health Agency (DHA) to Cerus Corporation, a biomedical products company specializing in blood safety technologies and pathogen reduction systems. The contract, valued at $214,560.00, is for the delivery of INT2540B DROP SHIPMENT FOR PLATELET PROCESSING. This contract has no set-aside designation. Cerus Corporation is the prime contractor and there are no major subcontractors identified. The contract supports medical...
This is a firm fixed price purchase order contract awarded by the Defense Health Agency to Cerus Corporation, a biomedical products company that manufactures the INTERCEPT Blood System technology for pathogen reduction in blood components. The contract is for the DROP SHIPMENT OF INTERCEPT DUAL, with a potential value of $66,624.00 and a completion date of January 1, 2024. Cerus Corporation, the prime contractor, is a for-profit manufacturer that has received over 20 federal contract awards from...
This is a firm fixed-price purchase order contract awarded by the Defense Health Agency (DHA) to Cerus Corporation, a biomedical company specializing in blood safety technologies and pathogen reduction systems. The contract is for the delivery of INTERCEPT Platelet Processing Sets, which are used to inactivate pathogens in blood platelets. The contract has a ceiling value of $295,760.00 and an ultimate completion date of January 31, 2022. Cerus Corporation has consistently secured sole-source...
This is a firm-fixed price purchase order awarded by the Veterans Integrated Service Network 12 (VISN 12), a civilian agency within the Department of Veterans Affairs, to Cerus Corporation, a biomedical company specializing in blood safety technologies and pathogen reduction systems. The $82,389 contract is for the supply of INTERCEPT Illuminator 60 Hz systems and associated maintenance services. The illuminators are essential components of Cerus Corporation's proprietary INTERCEPT Blood System,...
This firm-fixed-price purchase order was awarded by the Defense Health Agency to Cerus Corporation, a biomedical products company, for the provision of INTERCEPT Platelet Processing Sets. Valued at $137,664.00, the contract does not have a set-aside designation. Cerus has received over 20 previous prime federal contract awards from agencies including the DoD, VA, and HHS to provide pathogen reduction technologies, equipment, and associated services to support military and veterans' medical...
The Department of the Navy Bureau of Medicine and Surgery awarded a firm fixed price purchase order to Cerus Corporation, a biomedical products manufacturer, for the procurement of 2 INTERCEPT ILLUMINATOR 60HZ - INT100-60 units. The $110,000.00 contract has a completion date of September 8, 2017. Cerus Corporation has received over 20 prime federal contracts from agencies such as the Defense Health Agency, Department of Defense, and Department of Veterans Affairs to provide goods and services...
This is a $282,450,108.67 federal contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency, to Cerus Corporation. The contract is for the development and implementation of Cerus's proprietary pathogen reduction technology (PRT) known as the INTERCEPT Blood System. The INTERCEPT system uses riboflavin and ultraviolet light to inactivate pathogens in blood components, helping to reduce the risk of transfusion-transmitted infections. The...